比较结构化随访监测与常规照护用于NHS助听器新使用者的整群随机对照试验:FAMOUS试验方案
FAMOUS试验为多中心、两臂平行整群随机对照试验,纳入36家NHS听力学服务机构,比较结构化照护(含个性化行动计划、早期监测及验配后6周常规随访)与常规照护(验配后6-12周提供随访)对新成人助听器使用者助听器使用的影响,主要结局为12个月时自报每日助听器使用,采用意向性治疗分析。
要点
- 结构化照护组在验配后6周进行常规随访,常规照护组在验配后6-12周提供随访。
- 主要结局为12个月时自报每日助听器使用,次要结局包括生活质量、听力相关残疾及经济指标。
- 试验纳入36家NHS听力学服务机构,招募期3个月,数据分析采用混合效应回归模型。
核心结论
- FAMOUS试验旨在填补新助听器使用者随访照护潜在获益的证据缺口。
- 若干预成功,可利用现有设施在全国推广,对资源影响有限,并改善助听器使用和生活质量。
研究设计与样本
- 多中心、两臂平行组整群随机对照试验,包含内部预试验、经济学评价和过程评价。
- 纳入36家NHS听力学服务机构,比较新成人助听器使用者的两种随访方式。
- 招募通过参与机构在3个月内完成,从所有就诊患者的电子病历中采集伪匿名常规数据。
- 在验配后12周收集同意和结局;同意未来联系的患者在验配后12个月收集主要结局。
- 对干预组部分患者和听力专业人员进行定性访谈,评估可接受性和实施情况。
关键数值与推荐
- 结构化照护包括个性化行动计划、早期监测和验配后6周常规随访。
- 常规照护包括验配后6-12周提供随访。
- 主要结局为12个月时自报每日助听器使用。
- 次要结局包括生活质量、听力相关残疾和经济指标,在两个时间点收集。
- 统计分析采用意向性治疗框架下的混合效应回归模型。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hearing loss is a prevalent condition that impacts on social, mental and physical health, and has a significant economic burden. Hearing aids can improve the quality of life for those living with hearing loss; however, low and inconsistent use remains common. Within the National Health Service (NHS), follow-up care for new hearing aid users is highly variable and often lacks structure, which may contribute to low use. The FAMOUS trial investigates whether a structured care model for follow-up, combined with evidence-based behaviour change interventions, improves hearing aid use compared to usual care. METHODS: FAMOUS is a multi-centre, two-arm parallel-group cluster randomised controlled trial (CRCT) with integral internal pilot, economic, and process evaluations. The trial involves 36 NHS audiology services and compares two types of follow-up for new adult hearing aid users: structured care, which includes personalised action plans, early monitoring, and routine follow-up at 6 weeks post-fitting, to usual care, which includes the offer of a follow-up 6-12 weeks after fitting. Recruitment is conducted through participating services over 3 months, with pseudo-anonymised routine data collected from electronic medical records of all patients who attend. Consent and outcomes are then collected from patients at 12 weeks post-fitting. For patients who provide consent to future contact, the primary outcome (self-reported daily hearing aid use) is collected at 12 months post-fitting. Secondary outcomes (quality-of-life (QoL), hearing-related disability, and economic measures) are collected at both timepoints. Qualitative interviews with a subset of patients and hearing professionals in the intervention arm will assess the acceptability and implementation of the intervention. Statistical analyses, including mixed-effects regression modelling, will be conducted under an intention-to-treat framework. DISCUSSION: FAMOUS addresses a critical evidence gap regarding the potential benefits of follow-up care for new hearing aid users. If the intervention is successful, it can be rolled out nationally using existing facilities with limited impact on resources, identified in the economic analysis, and would improve hearing aid use and quality of life for those living with hearing loss. TRIAL REGISTRATION: Prospectively registered with the International Standard Randomised Controlled Trial Number (ISRCTN) 10589817. Date of registration: 01/09/2022.
引用
- Munro KJ, Armitage C, Elliott R, et al. Protocol for a cluster randomised controlled trial comparing structured Follow-up And Monitoring Of new USers of NHS hearing aids to usual care: the FAMOUS trial. Trials. 2025. PMID: 41194160. doi:10.1186/s13063-025-09188-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。